Increasing Effort by Pharmaceutical Players to Tap the Potential Diabetes Market in China
China is progressively moving towards diabetes disaster therby affecting the healthcare expenditure of the country. Approximately 37.2 Million diabetic patients are aware of their condition and this figure might go up in future. As per the increasing diabetes prevalence in China, the healthcare spending is likely to increase in future and growth of health insurance services will provide the market attractive for pharmaceutical players including Novo Nordisk, Sanofi, and Bayer.
View full press release